What are the methods for diagnosing pellagra (niacin deficiency)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnosis of Pellagra (Niacin Deficiency)

The diagnosis of pellagra primarily relies on clinical recognition of the classic triad of symptoms (dermatitis, diarrhea, dementia) and assessment of risk factors, with laboratory confirmation through measurement of urinary niacin metabolites when available. 1

Clinical Diagnostic Approach

Primary Clinical Features (The "3Ds" or "4Ds")

  • Dermatitis: Bilaterally symmetrical erythema on sun-exposed areas
    • Typically affects face, neck, dorsa of hands, and chest
    • Initially resembles sunburn, may progress to vesicles and bullae
    • Pruritus and burning sensation are common
  • Diarrhea: Chronic or recurrent, typically watery
    • Associated with anorexia, nausea, and epigastric discomfort
    • Can lead to malnutrition and cachexia
    • May occasionally be bloody and mucoid
  • Dementia: Neuropsychiatric manifestations
    • Early: Photophobia, asthenia, depression
    • Progressive: Hallucinations, confusion, memory loss, psychosis
    • Advanced: Disorientation, delirium, stupor
  • Death: If left untreated 1, 2

Risk Factor Assessment

Identify high-risk populations:

  • Malnutrition (especially corn-based diets lacking niacin)
  • Chronic alcoholism
  • Gastrointestinal malabsorptive states
  • Prolonged diarrhea
  • Medication use: isoniazid, 5-fluorouracil, pyrazinamide, 6-mercaptopurine, anticonvulsants
  • Homelessness with irregular eating patterns
  • Carcinoid tumors
  • Metabolic disorders 1, 2, 3, 4

Laboratory Diagnosis

When clinical features suggest pellagra, laboratory confirmation may be pursued:

Urinary Metabolite Testing (Preferred Method)

  • Measurement of urinary niacin metabolites:
    • N-methyl-nicotinamide (NMN)
    • N-methyl-2-pyridone-carboxamide (2-Pyr)
    • Low levels indicate niacin deficiency
    • NMN is most sensitive to marginal niacin intake
  • Testing methods:
    • HPLC with ultraviolet detection
    • HPLC coupled to tandem mass spectrometry (HPLC-MS/MS) - provides improved throughput, selectivity, and sensitivity 1

Blood Testing

  • Measurement of pyridine nucleotide levels:
    • Erythrocyte NAD or ratio of NAD to NADP (niacin index)
    • Less reliable than urinary metabolites in clinical pellagra
    • More than 98% of total pyridine nucleotide pool is in erythrocyte fraction 1

Pragmatic Approach When Testing Is Unavailable

When laboratory testing is difficult to arrange:

  • Store a blood sample
  • Initiate niacin supplementation
  • Observe for clinical response
  • Resolution of symptoms after niacin therapy supports the diagnosis 1

Diagnostic Pitfalls and Caveats

  • Incomplete presentation: Not all patients present with the full triad of symptoms
  • Misdiagnosis: Dermatitis may be misdiagnosed as sunburn or other skin conditions
  • Delayed diagnosis: Neuropsychiatric symptoms may be attributed to other causes
  • Concomitant deficiencies: Often occurs with other vitamin and zinc deficiencies
  • Subclinical deficiency: May present with subtle symptoms before full syndrome develops 2, 5

Treatment Approach Following Diagnosis

Once diagnosed, treatment should include:

  • Nicotinic acid (15-20 mg/day) or nicotinamide (300 mg/day)
  • Other B vitamins, zinc, and magnesium
  • Diet rich in calories and niacin sources
  • Topical emollients for skin lesions
  • Parenteral nutrition should provide at least 40 mg of niacin per day
  • Enteral nutrition should provide 18-40 mg per day of niacin in 1500 kcal 1, 2

Prevention

  • Nutritional education about food sources of niacin:
    • Meat, poultry, fish
    • Eggs, nuts, legumes
    • Whole grains
  • Avoidance of alcohol
  • Regular monitoring of at-risk populations 1, 6, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Pellagra].

Sante (Montrouge, France), 2005

Research

Isoniazid-induced pellagra.

Cutaneous and ocular toxicology, 2011

Research

Pellagra in 2 homeless men.

Mayo Clinic proceedings, 2001

Research

[Skin Manifestations of Pellagra].

Brain and nerve = Shinkei kenkyu no shinpo, 2019

Guideline

Weight Loss and Energy Enhancement Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.